Exhibit
10.22


 


FIRST
AMENDMENT TO LICENSE AGREEMENT


 


This
FIRST AMENDMENT, dated as of June 11, 20121 (this “First Amendment”), to the License Agreement, dated as of May 2, 2021 (the
“Agreement”), is entered into by and between Sonnet Biotherapeutics, Inc. (“Sonnet”) and New Life Therapeutics
PTE, Ltd (“New Life”). Unless otherwise set forth herein, capitalized terms used herein shall have the meanings set forth
in the Agreement.


 


W
I T N E S S E T H


 


WHEREAS,
Sonnet and New Life entered into the License Agreement dated May 2, 2021 pursuant to which Sonnet granted New Life, inter alia,
an exclusive license to Develop and Commercialize the Product in the DPN Field in the Exclusive Territory; and


 


WHEREAS,
the Parties hereto wish to amend the Agreement, as provided for in this First Amendment;


 


NOW,
THEREFORE, in consideration of the mutual covenants, conditions and agreements set forth herein and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:


 


1.
The Preamble shall be amended to delete the reference to SONNET BIOTHERAPEUTICS, INC. and replaced with SONNET BIOTHERAPEUTICS CH SA.
All subsequent references in the Agreement to Sonnet shall be deemed to be a reference to SONNET BIOTHERAPEUTICS CH SA.


 


2.
Except as specifically amended above, all terms and conditions of the Agreement shall remain in full force and effect and are hereby
ratified and confirmed.


 


3.
This First Amendment may be executed in one or more counterparts that together shall constitute a single agreement. If any provisions
of this First Amendment shall be held to be illegal, invalid or unenforceable under any applicable law, then such contravention or invalidity
shall not invalidate the entire First Amendment. Such provision shall be deemed to be modified to the extent necessary to render it legal,
valid and enforceable, and if no such modification shall render it legal, valid and enforceable, then this First Amendment shall be construed
as if not containing the provision held to be invalid, and the rights and obligations of the Parties shall be construed and enforced
accordingly.


 


[Signature
page follows]


 




    	 



     


    

 


IN
WITNESS WHEREOF, the Parties have executed this First Amendment as of the date first above written.


 


	 	SONNET
    BIOTHERAPEUTICS, INC.
	 	 	 
	 	By:	/s/
    Pankaj Mohan, Ph.D.
	 	Name:
    	Pankaj
    Mohan, Ph.D.
	 	Title:
    	Founder
    and Chief Executive Officer
	 	 	 
	 	By:	/s/
    Stephen J. McAndrew, Ph.D.
	 	Name:
    	Stephen
    J. McAndrew, Ph.D.
	 	Title:
    	Vice
    President, Business Development
	 	 	 
	 	NEW
    LIFE THERAPEUTICS PTE, LTD
	 	 	 
	 	By:	/s/
    Rakesh K. Aggarwal 
	 	Name:
    	Rakesh
    K. Aggarwal
	 	Title:
    	Chief
    Executive Officer
	 	 	 
	 	By:	/s/
    Rachna Kairon, M.D.
	 	Name:
    	Rachna
    Kairon, M.D.
	 	Title:
    	Chief
    Operating Officer
	 	 	 
	 	SONNET
    BIOTHERAPEUTICS CH SA
	 	 	 
	 	By:	/s/
    Pankaj Mohan, Ph.D.
	 	Name:
    	Pankaj
    Mohan, Ph.D.
	 	Title:
    	Chairman
    of the Board of Directors
	 	 	 
	 	By:	/s/
    Gael Hédou, Ph.D.
	 	Name:
    	Gael
    Hédou, Ph.D.
	 	Title:
    	Chief
    Operating Officer